Last reviewed · How we verify
Acute maxillary sinusitis
Approved treatments
- Cefpodoxime Proxetil · Pfizer
- Ceftin · GSK
Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death. - Ciprofloxacine · Poitiers University Hospital
- Vantin
- Zinacef · GSK
Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Noroxin
- Floxin
- Cipro · Bayer AG
- Biaxin · Generic (originally Abbott/AbbVie)
Clarithromycin is a macrolide antimicrobial drug. - Levaquin · Generic (originally Daiichi Sankyo/J&J)
Levofloxacin is a fluoroquinolone antibacterial agent. - Ofloxacine · Assistance Publique - Hôpitaux de Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute maxillary sinusitis patent landscape — cliff calendar, originator estates, attackable patents
- Acute maxillary sinusitis treatment landscape brief
- Acute maxillary sinusitis treatment updates RSS
Frequently asked questions about Acute maxillary sinusitis
What drugs treat Acute maxillary sinusitis?
Tracked treatments include Cefpodoxime Proxetil, Ceftin, Ciprofloxacine, Vantin, Zinacef, Noroxin, Floxin, Cipro.
What is the treatment for Acute maxillary sinusitis?
Standard treatment for Acute maxillary sinusitis includes Cefpodoxime Proxetil, Ceftin, Ciprofloxacine, Vantin, Zinacef. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acute maxillary sinusitis patent cliff · Acute maxillary sinusitis CI report
- Treatment: Cefpodoxime Proxetil · Pfizer
- Treatment: Ceftin · GSK
- Treatment: Ciprofloxacine · Poitiers University Hospital
- Treatment: Vantin
- Treatment: Zinacef · GSK
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing